Terms: = Lymphoma AND BRD4, O60885, 23476, ENSG00000141867, HUNKI, CAP, MCAP AND Prognosis
18 results:
1. Analysis of the genomic landscape of primary central nervous system lymphoma using whole-genome sequencing in Chinese patients.
Yuan X; Yu T; Zhao J; Jiang H; Hao Y; Lei W; Liang Y; Li B; Qian W
Front Med; 2023 Oct; 17(5):889-906. PubMed ID: 37418076
[TBL] [Abstract] [Full Text] [Related]
2. NCBP1 enhanced proliferation of DLBCL cells via METTL3-mediated m6A modification of c-Myc.
Meng S; Xia Y; Li M; Wu Y; Wang D; Zhou Y; Ma D; Ye J; Sun T; Ji C
Sci Rep; 2023 May; 13(1):8606. PubMed ID: 37244946
[TBL] [Abstract] [Full Text] [Related]
3. Oncolytic strategy using new bifunctional HDACs/brd4 inhibitors against virus-associated lymphomas.
Chen J; Wang Z; Phuc T; Xu Z; Yang D; Chen Z; Lin Z; Kendrick S; Dai L; Li HY; Qin Z
PLoS Pathog; 2023 Jan; 19(1):e1011089. PubMed ID: 36638143
[TBL] [Abstract] [Full Text] [Related]
4. The CDK4/6-UCHL5-brd4 axis confers resistance to BET inhibitors in MLL-rearranged leukemia cells by suppressing brd4 protein degradation.
Amari K; Sasagawa S; Imayoshi N; Toda Y; Hosogi S; Imamura T; Ashihara E
Biochem Biophys Res Commun; 2022 Jan; 588():147-153. PubMed ID: 34954522
[TBL] [Abstract] [Full Text] [Related]
5. The Inhibitor of Apoptosis Protein Livin Confers Resistance to Fas-Mediated Immune Cytotoxicity in Refractory lymphoma.
Sugihara E; Hashimoto N; Osuka S; Shimizu T; Ueno S; Okazaki S; Yaguchi T; Kawakami Y; Kosaki K; Sato TA; Okamoto S; Saya H
Cancer Res; 2020 Oct; 80(20):4439-4450. PubMed ID: 32928920
[TBL] [Abstract] [Full Text] [Related]
6. Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells.
Cortiguera MG; García-Gaipo L; Wagner SD; León J; Batlle-López A; Delgado MD
Sci Rep; 2019 Nov; 9(1):16495. PubMed ID: 31712669
[TBL] [Abstract] [Full Text] [Related]
7. Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors.
Li W; Gupta SK; Han W; Kundson RA; Nelson S; Knutson D; Greipp PT; Elsawa SF; Sotomayor EM; Gupta M
J Hematol Oncol; 2019 Jul; 12(1):73. PubMed ID: 31288832
[TBL] [Abstract] [Full Text] [Related]
8. Molecular profiling of adult acute myeloid and lymphoid leukemia in a major referral center in Lebanon: a 10-year experience report and review of the literature.
Assaf N; El-Cheikh J; Bazarbachi A; Salem Z; Farra C; Chakhachiro Z; Nassif S; Zaatari G; Mahfouz R
Mol Biol Rep; 2019 Apr; 46(2):2003-2011. PubMed ID: 30701458
[TBL] [Abstract] [Full Text] [Related]
9. NF-κB signaling and its relevance to the treatment of mantle cell lymphoma.
Balaji S; Ahmed M; Lorence E; Yan F; Nomie K; Wang M
J Hematol Oncol; 2018 Jun; 11(1):83. PubMed ID: 29907126
[TBL] [Abstract] [Full Text] [Related]
10. [Clinical analysis of 140 cases of mantle cell lymphoma].
Hu MW; Lou YJ; Yang M; Wang HF; Wang L; Jin J
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):390-395. PubMed ID: 29860768
[No Abstract] [Full Text] [Related]
11. Antileukemic Efficacy of BET Inhibitor in a Preclinical Mouse Model of MLL-AF4
Bardini M; Trentin L; Rizzo F; Vieri M; Savino AM; Garrido Castro P; Fazio G; Van Roon EHJ; Kerstjens M; Smithers N; Prinjha RK; Te Kronnie G; Basso G; Stam RW; Pieters R; Biondi A; Cazzaniga G
Mol Cancer Ther; 2018 Aug; 17(8):1705-1716. PubMed ID: 29748211
[No Abstract] [Full Text] [Related]
12. [Treatment for mantle cell lymphoma].
Izutsu K
Rinsho Ketsueki; 2017; 58(10):2026-2032. PubMed ID: 28978845
[TBL] [Abstract] [Full Text] [Related]
13. Evaluation of Testing of Acute Leukemia Samples: Survey Result From the College of American Pathologists.
George TI; Tworek JA; Thomas NE; Fatheree LA; Souers RJ; Nakhleh RE; Arber DA
Arch Pathol Lab Med; 2017 Aug; 141(8):1101-1106. PubMed ID: 28537804
[TBL] [Abstract] [Full Text] [Related]
14. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with brd4 inhibitors.
Gopalakrishnan R; Matta H; Tolani B; Triche T; Chaudhary PM
Oncogene; 2016 Apr; 35(14):1797-810. PubMed ID: 26119939
[TBL] [Abstract] [Full Text] [Related]
15. MMP7-mediated cleavage of nucleolin at Asp255 induces MMP9 expression to promote tumor malignancy.
Hsu TI; Lin SC; Lu PS; Chang WC; Hung CY; Yeh YM; Su WC; Liao PC; Hung JJ
Oncogene; 2015 Feb; 34(7):826-37. PubMed ID: 24632608
[TBL] [Abstract] [Full Text] [Related]
16. c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells.
Roderick JE; Tesell J; Shultz LD; Brehm MA; Greiner DL; Harris MH; Silverman LB; Sallan SE; Gutierrez A; Look AT; Qi J; Bradner JE; Kelliher MA
Blood; 2014 Feb; 123(7):1040-50. PubMed ID: 24394663
[TBL] [Abstract] [Full Text] [Related]
17. Clinical features and prognosis of follicular large-cell lymphoma: a report from the Nebraska lymphoma Study Group.
Anderson JR; Vose JM; Bierman PJ; Weisenberger DD; Sanger WG; Pierson J; Bast M; Armitage JO
J Clin Oncol; 1993 Feb; 11(2):218-24. PubMed ID: 8426197
[TBL] [Abstract] [Full Text] [Related]
18. Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin's lymphoma.
Armitage JO; Vose JM; Linder J; Weisenburger D; Harrington D; Casey J; Bierman P; Sorensen S; Hutchins M; Moravec DF
J Clin Oncol; 1989 Dec; 7(12):1783-90. PubMed ID: 2585020
[TBL] [Abstract] [Full Text] [Related]
